Chugai and Fuji Pharma enter agreement over cancer drug

Chugai Pharmaceutical and Fuji Pharma have entered into an agreement to transfer the rights to the manufacture and marketing of cancer drug Vesanoid (tretinoin) in Japan.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

Chinese biotech strikes billion dollar deal in nextgen cancer race

20 January 2026 Magic Circle and major US firm among dealmakers who worked on the licensing agreement for a bispecific antibody candidate, marking another significant outbound licensing deal from China’s biopharma sector.

Asia

Novo Nordisk secures China win ahead of key patent expiration

6 January 2026 Danish pharma giant notches an important victory in a huge market for semaglutide, but faces a patent cliff and mounting challenges across India, Canada and the US.

Asia

Novo Nordisk ramps up semaglutide defence as generics lurk

9 December 2025 The Danish pharma giant is expanding its patent defence in India as multiple generics prepare to challenge its blockbuster diabetes and weight-loss drug ahead of 2026 patent expiry.

More features

AI is transforming top 100 innovators, shows index

Novartis win blocks generics relitigating $7.8bn heart drug patent

Leading the arena: WIPR identifies the top US trade secrets specialists of 2025

Cadwalader global head among trio moving to Orrick

Skinny labels, big stakes: SCOTUS lines up the case of the year

Chinese biotech strikes billion dollar deal in nextgen cancer race

$5.4bn medtech leader fails to bury a rival's patent

Senior four-partner team leaves A&O Shearman

Chugai and Fuji Pharma enter agreement over cancer drug

More on this story

Editor's picks

Editor's picks

More features